# Gilead Sciences, Inc. (GILD) — Q1-2026 Earnings Results

**Report date:** 2026-05-07 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q1-2026

## Analyst Estimates

- **Consensus EPS:** $1.91 (range $1.74–$2.06)
- **Consensus revenue:** $6929.17

## Post-Earnings Brief

### Headline

Gilead Sciences Beats on EPS, Stock Down 1.64%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.03 | $1.91 | +7.69% |
| Revenue | N/A | $6.9B | N/A |

### Management Commentary

**Tone:** Unknown

No transcript is on record for this earnings call, so the analysis is based solely on numerical results.

### Guidance Changes

No forward guidance was provided in this earnings report.

### What It Means

Gilead Sciences reported better-than-expected earnings per share, but did not provide revenue figures or future guidance. The stock reacted negatively, declining by 1.64%, which may reflect investor concerns over the lack of revenue details and future outlook.

## Pre-Earnings Brief

### Company Snapshot

Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases, particularly in the fields of HIV, liver diseases, and oncology. With a market cap of $169 billion, Gilead plays a significant role in the healthcare sector, addressing critical health challenges and advancing treatment options.

### Key Metrics to Watch

- **EPS** (consensus $1.91) — Earnings per share is a key indicator of profitability and will show how well Gilead is managing costs and generating income.
- **Revenue** (consensus $6.9B) — Total revenue reflects the company's sales performance and growth trajectory, which is crucial for investor confidence.

### Last Quarter Recap

In Q4 2025, Gilead reported an EPS of $1.86, exceeding expectations by 1.92%. However, the stock dropped 2.93% the following day, indicating market caution despite the earnings beat.

### Wall Street Expectations

Analysts expect Gilead to report solid earnings this quarter, with a consensus EPS of $1.91 and revenue of $6.9 billion. Investors will be closely watching for any signs of growth in key therapeutic areas.

**Bull case:** If Gilead exceeds EPS and revenue expectations, it could signal strong demand for its products and a positive outlook for future growth, potentially boosting investor confidence.

**Bear case:** Conversely, if Gilead misses estimates or provides weak guidance, it could raise concerns about its market position and future profitability, leading to a negative reaction.

### Options Signal

Implied move: **4.88%**

The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility.

### Earnings Track Record

| Quarter | EPS Surprise | 1-Day Reaction |
|---|---|---|
| Q4-2025 | +1.92% | -2.93% |
| Q3-2025 | +14.62% | -0.05% |
| Q2-2025 | +0.80% | +0.00% |
| Q1-2025 | +3.31% | -0.22% |
| Q4-2024 | +13.91% | +0.69% |
| Q3-2024 | +28.01% | +1.63% |
| Q2-2024 | +25.08% | +2.15% |
| Q1-2024 | +11.47% | -2.70% |

### Pivotal Questions

1. **Will Gilead's EPS exceed the consensus estimate of $1.91?**
   - Why it matters: A beat on EPS would reinforce confidence in Gilead's profitability and growth potential, impacting stock performance.
2. **What guidance will Gilead provide regarding future revenue growth?**
   - Why it matters: Future revenue guidance will be critical for investor sentiment, as it indicates the company's outlook in a competitive market.

### Thesis Break Levels

- **Bull trigger:** Exceeding an EPS of $1.91 and revenue of $6.9 billion would confirm a strong performance.
- **Bear trigger:** Falling short of the consensus EPS and revenue expectations would signal potential challenges ahead.

The market is focused on Gilead's ability to maintain profitability and growth in a competitive biotechnology landscape.

### Scenario Playbook

- **Beat & raise:** If Gilead beats expectations, history suggests the stock could see a positive reaction, potentially around a 1.3% move upwards.
- **In-line / cautious:** If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess future growth.
- **Miss:** Should Gilead miss estimates, history indicates a potential drop, with an average reaction of around -0.18% when they beat.

### What the Street is Missing

The Street may underestimate Gilead's potential for revenue growth in emerging markets, where demand for its therapies is increasing.

**Supporting points:**

- Recent insider selling may indicate a lack of confidence in the near-term performance, which could affect investor sentiment.
- Options pricing suggests a larger move than historical averages, indicating heightened uncertainty that may not align with actual performance.

**Risk to consensus:** If Gilead's revenue growth in emerging markets exceeds expectations, it could challenge the current consensus.

### What to Listen For

- Any updates on new product launches or pipeline developments.
- Details on revenue performance from key therapeutic areas.
- Management's outlook on market conditions and competitive landscape.
- Insights into cost management and operational efficiency.
- Any commentary on international market expansion efforts.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q1-2026_